Full Press Release Details
CorMedix Granted Extension of NYSE MKT
Bridgewater, New Jersey, February 7, 2013
(Business Wire) - CorMedix Inc. ("CorMedix") (NYSE MKT: CRMD), a pharmaceutical company focused on developing
and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, announces the receipt of notice
on February 1, 2013 from the NYSE MKT LLC (the "NYSE MKT") that the NYSE MKT granted it an extension until April 15,
2013 to regain compliance with the continued listing standards of the NYSE MKT. The NYSE MKT is continuing CorMedix's listing
pursuant to the extension. CorMedix will be subject to periodic review by the NYSE MKT during the extension period. Failure to
make progress consistent with the plan or to regain compliance with continued listing standards by the end of the extension period
could result in CorMedix being delisted from the NYSE MKT.
CorMedix previously received notice on
April 20, 2012 from the NYSE MKT informing it that CorMedix was below certain of the NYSE MKT's continued listing standards
due to financial impairment as set forth in Section 1003(a)(iv) of the NYSE MKT Company Guide. CorMedix was afforded the opportunity
to submit a plan to the NYSE MKT to regain compliance and, on May 17, 2012, presented its plan to the NYSE MKT. On June 27, 2012,
the NYSE MKT accepted CorMedix's plan and granted it an extension until August 22, 2012 to regain compliance with the continued
listing standards. On September 21, 2012, the NYSE MKT notified CorMedix that it granted CorMedix another extension to January
31, 2013 to regain compliance with the NYSE MKT continued listing standards.
CorMedix Inc. is a pharmaceutical company
that seeks to in-license, develop and commercialize therapeutic products for the prevention and treatment of cardiac and renal
dysfunction, also known as cardiorenal disease. CorMedix most advanced product candidate: CRMD003 (Neutrolin ) for
the prevention of catheter related bloodstream infections and maintenance of catheter patency in tunneled, cuffed, central venous
catheters used for vascular access in hemodialysis patients. Please see www.cormedix.com for additional information.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
1995 that are subject to risks and uncertainties. All statements, other than statements of historical facts, regarding management's
expectations, beliefs, goals, plans or CorMedix's prospects, future financial position, future revenues and projected costs should
be considered forward-looking. Readers are cautioned that actual results may differ materially from projections or estimates due
to a variety of important factors, including: CorMedix's ability to maintain its listing on the NYSE MKT; obtaining regulatory
approvals to conduct clinical trials and to commercialize CorMedix's product candidates, including CE Marking for Neutrolin
in Europe; the outcome of clinical trials of CorMedix's product candidates and whether they demonstrate these candidates' safety
and effectiveness; the risks and uncertainties associated with CorMedix's ability to manage its limited cash resources, obtaining
additional financing to support CorMedix's research and development and clinical activities and operations; CorMedix's ability
to enter into and maintain collaborations with third parties for its development programs; CorMedix's dependence on its collaborations
and its license relationships; achieving milestones under CorMedix's collaborations; CorMedix's dependence on preclinical and clinical
investigators, preclinical and clinical research organizations, manufacturers and consultants; and protecting the intellectual
property developed by or licensed to CorMedix. These and other risks are described in greater detail in CorMedix's filings with
the SEC, copies of which are available free of charge at the SEC's website at www.sec.gov or upon request from CorMedix.
CorMedix may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place
undue reliance on these statements. CorMedix assumes no obligation and does not intend to update these forward-looking statements,
except as required by law.
Chief Executive Officer